Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Fineline Cube Jul 20, 2026
Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Fineline Cube Jul 20, 2026
Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Fineline Cube Jul 20, 2026
Company Drug

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

Fineline Cube Jul 20, 2026
Company Deals

Sinopharm Partners with Biogen for Comprehensive Service Agreement

Fineline Cube Jan 26, 2025

China-based Sinopharm Group Co., Ltd (HKG: 1099) has entered into a strategic partnership with US-based...

Company Drug

Boehringer Ingelheim’s Nerandomilast Granted Priority Review for IPF in China

Fineline Cube Jan 26, 2025

German pharmaceutical giant Boehringer Ingelheim has announced that the Center for Drug Evaluation (CDE) of...

Company Deals

Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits

Fineline Cube Jan 26, 2025

Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing...

Company Drug

Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts

Fineline Cube Jan 26, 2025

Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the...

Company Medical Device

Huadong Medicine’s Ellansé M Filing Accepted by China’s NMPA

Fineline Cube Jan 26, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the...

Company Digital Drug

China Medical System Partners with MabGeek for Innovative Drug MG-K10

Fineline Cube Jan 26, 2025

China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...

Company Drug

BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062

Fineline Cube Jan 25, 2025

BioCity Biopharma, a leading biopharmaceutical company, has announced the initiation of a Phase III clinical...

Company Deals

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline

Fineline Cube Jan 24, 2025

ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million...

Company Drug

Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA

Fineline Cube Jan 24, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for...

Company Deals

AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology

Fineline Cube Jan 24, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...

Company Medical Device

Sino Medical Sciences Wins Peru Approval for Coronary Balloon Catheter

Fineline Cube Jan 24, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval from Peru’s...

Company Drug

Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus

Fineline Cube Jan 24, 2025

China-based stem cell specialist Shenzhen Beike Biotechnology Co., Ltd has announced the initiation of a...

Company Medical Device

Accuray’s Tomo C System Completes Treatment of First 100 Patients in China

Fineline Cube Jan 24, 2025

US-based medical device firm Accuray Inc. (NASDAQ: ARAY) has announced the completion of treating the...

Company Deals

Ascentage Pharma Prices US IPO at USD 17.25 per ADS

Fineline Cube Jan 24, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public...

Company Drug

United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA

Fineline Cube Jan 24, 2025

Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...

Company Drug

Beijing Aosaikang’s ASKB589 Shows Promise in Phase I/II Study for Gastric Cancer

Fineline Cube Jan 24, 2025

China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has unveiled the latest results from a...

Company Drug

Biogen’s Higher-Dose Spinraza Regimen Under Review by FDA and EMA

Fineline Cube Jan 24, 2025

US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has submitted supplemental New Drug Applications (sNDAs) to the...

Company Deals

Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease

Fineline Cube Jan 24, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement...

Company

Zai Lab’s ZL-1310 Granted Orphan Drug Designation by FDA for SCLC

Fineline Cube Jan 23, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that the US Food...

Company Deals

Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies

Fineline Cube Jan 23, 2025

Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its...

Posts pagination

1 … 252 253 254 … 697

Recent updates

  • Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms
  • China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure
  • CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years
  • Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China
  • Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Policy / Regulatory

China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure

Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.